Listeria monocytogenes-based bivalent Lm-LLO immunotherapy for the treatment of HER2/neu positive and triple negative breast cancer and its impact on immunosuppression

被引：0
|
作者：
Wallecha, A. [1 ]
Ramos, K. [1 ]
Malinina, I. [1 ]
Singh, R. [1 ]
机构：
[1] Advaxis Inc, Princeton, NJ USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P4-04-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-04-05
引用
收藏
页数：1
相关论文
共 50 条
  • [21] HER2 Evaluation and Its Impact on Breast Cancer Treatment Decisions
    Goddard, K. A. B.
    Weinmann, S.
    Richert-Boe, K.
    Chen, C.
    Bulkley, J.
    Wax, C.
    PUBLIC HEALTH GENOMICS, 2012, 15 (01) : 1 - 10
  • [22] Behaviour and metastatic potential of her2/neu positive and her2/neu negative circulating epithelial tumor cells (CETC) during adjuvant systemic therapy in breast cancer
    Camara, O.
    Hammer, U.
    Gajda, M.
    Kroll, T.
    Krauspe, S.
    Gellner, A-K
    Joerke, C.
    Runnebaum, I. B.
    Hoeffken, K.
    Pachmann, K.
    CANCER RESEARCH, 2009, 69 (02) : 310S - 310S
  • [23] Prognostic Impact of Delaying Multimodality Treatment in HER2 Positive Breast Cancer
    Chang, Helena
    Gornbein, Jeffrey
    Lim, Sin Yee
    CANCER RESEARCH, 2023, 83 (05)
  • [24] Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cells.
    Geradts, J
    Leek, R
    Harris, AL
    Wilson, KS
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 233 - 233
  • [25] Survival of metastatic hormone receptor (HR) positive/HER2 negative; HER2+; and triple negative (TN) breast cancer based on initial presentation
    den Brok, Wendie-Lou D.
    Speers, Caroline
    Lovedeep, Gondara
    Baxter, Emily
    Tyldesley, Scott
    Caroline, Lohrisch
    CANCER RESEARCH, 2015, 75
  • [26] IMPACT OF HORMONE RECEPTOR STATUS AND HER2 ON SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS
    Xiao, H.
    Tan, F.
    Huang, Y.
    Feldman, J.
    Koniaris, L.
    Gummadi, S.
    Adunlin, G. B.
    Ali, A. A.
    VALUE IN HEALTH, 2013, 16 (03) : A131 - A131
  • [27] Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC)
    Taylor, Melissa
    Reddy, Shilpa
    Kumar, Prashanth Ashok
    Hariri, Dana
    Sokol, Ethan
    Sivakumar, Smruthy
    Quintanilha, Julia
    Pavlick, Dean
    Levy, Mia Alyce
    Ross, Jeffrey S.
    Lustberg, Maryam B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Treatment of HER2 Positive Advanced Gastric Cancer: Deviations in HER2 Results and Its Impact on Survival
    Haffner, Ivonne
    Schierle, Katrin
    Maier, Dieter
    Geier, Birgitta
    Raimundez, Elba
    Hasenauer, Jan
    Luber, Birgit
    Kretzschmar, Albrecht
    von Weikersthal, Ludwig Fischer
    Ahlborn, Miriam
    Riera, Jorge
    Rau, Beate
    Siegler, Gabriele
    Fuxius, Stefan
    Decker, Thomas
    Wittekind, Christian
    Lordick, Florian
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 65 - 65
  • [29] Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer
    Rauch, Gaiane M.
    Li, Heng
    Zhu, Hongtu
    Adrada, Beatriz E.
    Santiago, Lumarie
    Candelaria, Rosalind P.
    Wang, Hao
    Leung, Jessica
    Thompson, Alastair
    Litton, Jennifer
    Wu, Yun
    Lim, Bora
    Moulder, Stacy
    Mittendorf, Elizabeth A.
    Yang, Wei
    CANCER RESEARCH, 2018, 78 (04)
  • [30] Survival Analysis of Triple Negative and Her2 Positive Breast Cancer Patients: Single Center Report
    Varol, Umut
    Cakar, Burcu
    Yildiz, Ibrahim
    Dalgic, Ceyda Tunakan
    Ozisik, Hatice
    Ozisik, Melih
    Karaca, Burcak
    Karabulut, Bulent
    Uslu, Ruhan
    JOURNAL OF BREAST HEALTH, 2014, 10 (01): : 42 - 46
12345